Abbott Laboratories stock slips as sellers dominate below major moving averages: weekly outlook

Traders Union
All News
Financial News
Abbott Laboratories slips 1.38% this week

Highlights

Abbott Laboratories is trading below key moving averages, signaling continued bearish control over both medium- and long-term trends.
Momentum and major indicators, including MACD and ADX, confirm a negative bias with a low probability of an imminent rebound.
ABT is forecast to trade between $92.97 and $95.06 in the next week, with a sideways or downward move most likely.

Product approvals and portfolio expansions temper institutional repositioning this week

The Volt pulsed field ablation system from Abbott Laboratories recently received CE mark approval, strengthening ABT's cardiac health product lineup. The company has also expanded its diabetes care portfolio through new partnerships. Additionally, Whittier Trust Co. reduced its stake in ABT during the first quarter, while institutional holders maintain a strong presence in the stock.

Bearish momentum holds as resistance and caution intensify over the week

Weekly technicals remain bearish, with ABT nestled in the upper segment of its recent range but continuing to face selling pressure. All major weekly moving averages (MA-20, MA-50, MA-200) act as overhead resistance and the closest dynamic resistance level is at MA-20 ($96.75). Weekly MACD signals strong sell, ADX confirms the prevailing downtrend, and RSI at 43.02 also reflects bearish territory. Oscillators such as the Stochastic RSI and Bull/Bear Power indicate lingering buyer activity, but CCI remains neutral, and overall momentum favors sellers. Notably, weekly volatility stands at 5.62%, with the tone increasingly cautious following a sustained decline.

Sideways consolidation likely as bearish bias and support risks shape outlook

Over the next five trading days, ABT is likely to move sideways with a range between $92.97 and $95.06, as none of the core weekly indicators signal a bullish reversal. There is a strong probability of continued consolidation with downside risk if support at $92.97 gives way. Should buyers regain control, a breakout above $95.06 would open the path to further upside, but current weekly metrics suggest sellers remain in control and a bearish or neutral outcome is most probable.

Viktoras Karapetjanc, Traders Union expert, believes Abbott Laboratories showed resilience despite downside pressure this week, with robust institutional backing supporting its long-term outlook. He notes that the recent CE mark for its Volt pulsed field ablation system and diabetes care partnerships highlight positive fundamental momentum. The analyst sees sideways movement as an opportunity for patient investors, given ABT’s clear leadership in healthcare innovation. As weekly momentum remains tilted toward sellers, he expects ranges to hold unless buyers reclaim $95.06. "With industry catalysts taking shape and strong institutional support, I see this consolidation phase as a constructive setup for future upside in the coming weeks."

In a recent review, analysts noted that bullish momentum in Abbott Laboratories was expected to persist, supported by positive technical signals and institutional interest. However, the current technical landscape marks a shift toward consolidation with mounting downside risks, making sustained closes above $95.06 the pivotal sign for any renewed bullish momentum.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.